Enter clinical variables to predict advanced hepatic fibrosis in NAFLD patients.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Non-invasive assessment of hepatic fibrosis stage in patients with diagnosed NAFLD or NASH.
Identifying patients who can safely avoid liver biopsy (low score, NPV > 93%).
Longitudinal monitoring of fibrosis progression or regression with lifestyle/pharmacotherapy.
Risk stratification for advanced hepatic complications (varices, HCC, liver failure).
Target Population
Adults with NAFLD, defined by hepatic steatosis on imaging or histology, in the absence of significant alcohol use (< 21 units/week men, < 14 units/week women) or other causes of chronic liver disease.
Diabetes and insulin resistance directly drive fibrogenesis via hepatic stellate cell activation. A rising AST/ALT ratio (normally < 1.0) indicates mitochondrial AST release as hepatocytes die in cirrhotic livers. Falling albumin and platelets reflect hepatic synthetic failure and portal hypertension respectively.
Section 3
Pearls/Pitfalls
Important Caveats
NFS is validated in NAFLD only — do NOT apply to other liver diseases (ALD, viral hepatitis).
Has 25% indeterminate zone, which limits usefulness; combine with FIB-4 for concordance testing.
BMI extremes (obesity class III, BMI > 40) reduce accuracy due to adipokine interference.
Diabetes diagnoses should be based on FPG or HbA1c, not imprecise clinical reporting.
NFS vs FIB-4 in NAFLD
When FIB-4 and NFS are concordant (both low or both high), diagnostic accuracy increases significantly. When discordant, FibroScan acts as the tiebreaker before committing to biopsy. This two-test strategy is recommended by EASL 2021.
Section 4
Next Steps
Management Pathway
01
NFS < −1.455 (Low): No biopsy needed. Intensive lifestyle intervention (≥7% weight loss). Repeat NFS in 2–3 years.
02
NFS Indeterminate: Proceed to FibroScan. If LSM < 8 kPa → reassure; if LSM > 10 kPa → refer Hepatology.
03
NFS > 0.676 (High): Refer to Hepatology. Consider biopsy for staging if treatment with a licensed NASH drug (e.g., resmetirom) is planned.
04
All NAFLD patients: Target < 7% total body weight loss, treat metabolic syndrome, consider GLP-1 RA for concurrent T2DM.
Section 5
Evidence Appraisal
Original Derivation
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Angulo P et al. • Hepatology. 2007;45(4):846-54. Derived from 733 patients at 4 international centres; validated internally and externally.
Section 6
Literature
Dr Paul Angulo — Mayo Clinic
Developed by Dr Paul Angulo and a multinational team in 2007. The study demonstrated that a combination of readily available laboratory and anthropometric variables could accurately identify advanced fibrosis in a disease that was historically only stageable by biopsy. As NAFLD prevalence has now surpassed viral hepatitis globally, the NFS has become critical for scalable, non-invasive disease management.
Last Comprehensive Review: 2026
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Non-invasive assessment of hepatic fibrosis stage in patients with diagnosed NAFLD or NASH.
Identifying patients who can safely avoid liver biopsy (low score, NPV > 93%).
Longitudinal monitoring of fibrosis progression or regression with lifestyle/pharmacotherapy.
Risk stratification for advanced hepatic complications (varices, HCC, liver failure).
Target Population
Adults with NAFLD, defined by hepatic steatosis on imaging or histology, in the absence of significant alcohol use (< 21 units/week men, < 14 units/week women) or other causes of chronic liver disease.
Diabetes and insulin resistance directly drive fibrogenesis via hepatic stellate cell activation. A rising AST/ALT ratio (normally < 1.0) indicates mitochondrial AST release as hepatocytes die in cirrhotic livers. Falling albumin and platelets reflect hepatic synthetic failure and portal hypertension respectively.
Section 3
Pearls/Pitfalls
Important Caveats
NFS is validated in NAFLD only — do NOT apply to other liver diseases (ALD, viral hepatitis).
Has 25% indeterminate zone, which limits usefulness; combine with FIB-4 for concordance testing.
BMI extremes (obesity class III, BMI > 40) reduce accuracy due to adipokine interference.
Diabetes diagnoses should be based on FPG or HbA1c, not imprecise clinical reporting.
NFS vs FIB-4 in NAFLD
When FIB-4 and NFS are concordant (both low or both high), diagnostic accuracy increases significantly. When discordant, FibroScan acts as the tiebreaker before committing to biopsy. This two-test strategy is recommended by EASL 2021.
Section 4
Next Steps
Management Pathway
01
NFS < −1.455 (Low): No biopsy needed. Intensive lifestyle intervention (≥7% weight loss). Repeat NFS in 2–3 years.
02
NFS Indeterminate: Proceed to FibroScan. If LSM < 8 kPa → reassure; if LSM > 10 kPa → refer Hepatology.
03
NFS > 0.676 (High): Refer to Hepatology. Consider biopsy for staging if treatment with a licensed NASH drug (e.g., resmetirom) is planned.
04
All NAFLD patients: Target < 7% total body weight loss, treat metabolic syndrome, consider GLP-1 RA for concurrent T2DM.
Section 5
Evidence Appraisal
Original Derivation
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Angulo P et al. • Hepatology. 2007;45(4):846-54. Derived from 733 patients at 4 international centres; validated internally and externally.
Section 6
Literature
Dr Paul Angulo — Mayo Clinic
Developed by Dr Paul Angulo and a multinational team in 2007. The study demonstrated that a combination of readily available laboratory and anthropometric variables could accurately identify advanced fibrosis in a disease that was historically only stageable by biopsy. As NAFLD prevalence has now surpassed viral hepatitis globally, the NFS has become critical for scalable, non-invasive disease management.
